Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591
Journal of Clinical Oncology · 01.03.2024 · 42 (7) · 842-851
DOI: 10.1200/jco.23.00573 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2024. Verfasst von Scott T Tagawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCRR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225 Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225. METHODS Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225 Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D. RESULTS Radiochemistry and animal studies were favorable. Thirty-two patients received 225 Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%). CONCLUSION To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225 Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
- Department of Urology, Weill Cornell Medicine, New York, NY.
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY.
- Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
- Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA.
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY.
ORCID-Profile: Scott T Tagawa, Charlene Thomas, A Oliver Sartor, Judith Stangl-Kremser, Sandra Huicochea Castellanos, Jones T Nauseef, Cora N Sternberg, Karla Ballman, Joseph R Osborne
Förderung
- NCI NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
Zitieren
APA
Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Huicochea Castellanos, S., Nauseef, J. T., Sternberg, C. N., Molina, A., Ballman, K., Nanus, D. M., Osborne, J. R., & Bander, N. H. (2024). Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591. Journal of Clinical Oncology, 42(7), 842-851. https://doi.org/10.1200/jco.23.00573
Vancouver
Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, et al. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591. Journal of Clinical Oncology. 2024;42(7):842-851. doi:10.1200/jco.23.00573
BibTeX
@article{Tagawa2024,
author = {Tagawa, Scott T and Thomas, Charlene and Sartor, A Oliver and Sun, Michael and Stangl-Kremser, Judith and Bissassar, Mahelia and Vallabhajosula, Shankar and Huicochea Castellanos, Sandra and Nauseef, Jones T and Sternberg, Cora N and Molina, Ana and Ballman, Karla and Nanus, David M and Osborne, Joseph R and Bander, Neil H},
title = {Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {7},
pages = {842--851},
doi = {10.1200/jco.23.00573}
}
EUVIMED